Comparative Pharmacology
Head-to-head clinical analysis: FORTOVASE versus TIVICAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORTOVASE versus TIVICAY.
FORTOVASE vs TIVICAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Saquinavir is a protease inhibitor that binds to the active site of HIV-1 protease, blocking the cleavage of viral polyprotein precursors into functional proteins, resulting in the production of immature, non-infectious viral particles.
Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration, which is essential for HIV replication.
1200 mg orally three times daily with food.
50 mg orally once daily, or 50 mg twice daily when coadministered with potent UGT1A1 inducers (e.g., rifampin). For INSTI-naive patients: 50 mg once daily. For INSTI-experienced patients with suspected resistance: 50 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is 1-2 hours in healthy subjects; prolonged to 2-5 hours in patients with hepatic impairment or when coadministered with ritonavir.
Terminal elimination half-life approximately 14 hours (range 11-20 hours) in healthy subjects; supports once-daily dosing with a low pharmacokinetic boost.
Primarily hepatic metabolism via CYP3A4; 2% excreted unchanged in urine, 15% unchanged in feces; extensive biliary excretion of metabolites.
Primarily metabolized by UGT1A1 with minor CYP3A4 contribution; 53% of dose excreted in feces (31% as unchanged drug) and 33% in urine (1% unchanged).
Category C
Category C
Antiretroviral
Antiretroviral, integrase inhibitor